for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

GSK, Vir apply for U.S. emergency use of COVID-19 antibody therapy

March 26 (Reuters) - GSK and Vir Biotechnology have filed an application to U.S. regulators for emergency use authorization of their antibody therapy to treat early-stage COVID-19 infections, the drugmakers said on Friday.

Earlier this month, the companies found their experimental treatment, VIR-7831, reduced the risk of hospitalization and deaths among patients by 85%, based on interim data from a study.

Reporting by Pushkala Aripaka in Bengaluru; Editing by Arun Koyyur

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up